Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Issue : The Pharmaceutical Journal, 3/10 January 2015, Vol 294, No 7843/4

Sort by: Newest first Oldest first A-Z Z-A

  • Smoking cessation – the Nazi method

    25 NOV 2014 By Steve Bremer

    Not renowned for its public health measures, Nazi Germany led the first anti-smoking campaign in modern history and was the most powerful anti-smoking movement in the world during the 1930s and early 1940s.

  • A rethink is needed about how medicines-related IT systems should work

    1 DEC 2014 By Andrew Davies
    Comments (2)

    Current initiatives to roll out patient record access to pharmacy provide insufficient patient information, and lack functionalities to ensure safe and efficient provision of services to patients. Moreover, access to these records have been patchy and wider access is needed, writes Andrew Davies.

  • The deep-fried Mars bar: an illustration of a bad diet?

    1 DEC 2014 By Pamela Mason

    After analysing a small study in healthy young adults, which found that eating deep-fried Mars bar caused a significant impairment in cerebrovascular reactivity in men, Pam Mason advises sticking to porridge for breakfast.

  • Text messages to patients prescribed blood pressure or lipid-lowering drugs improve medicine adherence

    Text messages can help patients adhere to their medicines Subscription

    9 DEC 2014 14:38

    A third of patients prescribed blood pressure or lipid-lowering drugs to prevent coronary heart disease or stroke fail to take their medicines properly, but text messages could improve adherence.

  • Tuesday 13 January: SW London Subscription

    10 DEC 2014 11:06

    Local practice forum event, ‘Centre for Pharmacy Postgraduate Education diabetes focal point’. Postgraduate Centre, Croydon University Hospital, 530 London Road, Croydon, Surrey CR7 7YE. Event 7.30pm, buffet 7pm. Email yourpesl@gmail.com to book.

  • Robert Dewar dies Subscription

    10 DEC 2014 16:17

    On 8 November, Robert Dewar MPharmS, aged 71, of 5 Mclarens Park, Gargunnock, Stirling FK8 3DG. Mr Dewar registered with the Society in 1965.

  • Drug tariff updates December 2014 Subscription

    11 DEC 2014 11:07

    The Department of Health and National Assembly for Wales have agreed concessionary prices for the following items for December 2014 prescriptions: amantadine capsules 100mg, £19.80; amiloride tablets 5mg, £14.05; co-amilofruse tablets 5/40mg, £4.80; co-tenidone tablets 50/12.5mg, £3.36; co-tenidone tablets 100/25mg, £3.55; fenofibrate micronised capsules 200mg, £12.00; pizotifen tablets 0.5mg, £5.78; ...

  • Qualified person: Angela Hallam Subscription

    11 DEC 2014 11:15

    Angela Hallam, MRPharmS, clinical trials and regulatory affairs pharmacist and strategic lead for clinical trials, Cardiff and Vale University Health Board, was added to the Royal Pharmaceutical Society’s Qualified Person (QP) register on 9 December 2014. Having successfully passed the Joint Professional Bodies’ QP viva, she is eligible to be named as a QP on manufacturers’ authorisations.

  • NICE options for anaemia in cancer patients Subscription

    11 DEC 2014 13:25

    The National Institute for Health and Care Excellence (NICE) has updated its guidance to expand the use of erythropoiesis-stimulating agents (ESAs) for people with cancer who are having chemotherapy and who have anaemia. ESAs boost levels of red blood cells. This decision increases the number of treatments available through the NHS.

  • Tamoxifen used in primary prevention cuts the risk of breast cancer by around 30% and this benefit endures for at least 20 years

    Chemoprevention with tamoxifen cuts risk of breast cancer by almost 30% Subscription

    11 DEC 2014 14:24 By Joanna Lyford

    Tamoxifen used in primary prevention cuts the risk of breast cancer by around 30% and this benefit lasts for at least 20 years, a long-term follow-up of the International Breast Cancer Intervention Study shows.

Show  10 per page20 per page50 per page

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.